HEPPAR1 and PIWIL2 as Panel Markers for Hepatocellular Carcinoma

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• Hepatocellular Carcinoma (HCC) is a significant global health concern.
• Accurate diagnostic and prognostic markers for HCC are crucial for effective patient management.
• PIWI-like protein-2 (PIWIL2) and HepPar1 are potential biomarkers under investigation.

Purpose of the Study:

• To evaluate the expression profiles of PIWIL2 and HepPar1 in HCC.
• To assess the immunohistochemical (IHC) characteristics of PIWIL2 and HepPar1 in HCC.
• To determine the correlation of PIWIL2 and HepPar1 with clinicopathological parameters for diagnostic value.

Main Methods:

• Seventy-five HCC patients' serum and tissue samples were analyzed.
• Real-time polymerase chain reaction (RT-PCR) was used to detect PIWIL2 expression.
• Immunohistochemistry (IHC) was performed for PIWIL2 and HepPar1 detection.

Main Results:

• PIWIL2 levels were significantly higher in HCC compared to controls (p≤0.001).
• HepPar1 and PIWIL2 were detected in 84% of HCC cases.
• Both markers demonstrated significant diagnostic and prognostic value in tissue and serum samples (p<0.001).

Conclusions:

• PIWI expression reactivation is crucial for cancer development.
• PIWIL2 and HepPar1 show promise as a combined diagnostic panel for HCC.
• Further validation may enhance HCC diagnosis and patient stratification.